If You Invested in Harrow, Inc. 11.875% Senior Notes due 2027 (HROWM)
See the HROWM overviewWhat $1,000 or $10,000 in HROWM Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since Dec 21, 2022 |
|---|---|---|---|---|
| $1,000 | $968 -3% | — | — | $1,053 +5% |
| $10,000 | $9,677 -3% | — | — | $10,530 +5% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2025-10-08. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for HROWM$1,000 Investment Over Time
HROWM vs S&P 500Year-by-Year Returns
HROWM annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2022Dec 21, 2022 to Dec 30, 2022 | $24.72 | $25.08 | +1.5% | +1.5% |
| 2023 | $25.08 | $25.80 | +2.9% | +4.4% |
| 2024 | $25.80 | $26.21 | +1.6% | +6.0% |
| 2025Dec 31, 2024 to Oct 8, 2025 | $26.21 | $26.03 | -0.7% | +5.3% |
About Harrow, Inc. 11.875% Senior Notes due 2027
NASDAQ
HROWM is the ticker symbol for a series of senior notes issued by Harrow, Inc., a company in the pharmaceutical preparations sector. According to an SEC filing, these securities are identified as 11.875% Senior Notes due 2027 and are listed on The Nasdaq Stock Market LLC under the symbol HROWM. While Harrow, Inc. is the operating company, HROWM represents its debt securities rather than common equity.
The available regulatory disclosure indicates that Harrow, Inc. operates in the pharmaceutical preparations sector. Investors researching HROWM are therefore looking at a fixed-income instrument tied to a pharmaceutical-focused issuer. The notes have a stated interest rate and maturity year, which define their basic structure as senior notes.
Harrow, Inc. also has other securities registered, including 8.625% Senior Notes due 2026 listed on Nasdaq under the symbol HROWL, and common stock with a par value per share referenced under the symbol HROW. This context helps investors understand that HROWM exists within a broader capital structure that includes both equity and other debt securities.
Auditor changes and governance context
In an 8-K report, Harrow, Inc. disclosed a change in its independent registered public accounting firm. The company’s audit committee dismissed Crowe LLP as the independent registered public accounting firm and approved the appointment of Deloitte & Touche LLP to audit the company’s consolidated financial statements for a subsequent fiscal year, subject to standard client acceptance procedures and an engagement letter. The filing states that Crowe’s report on the company’s financial statements for a referenced year did not contain an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles.
The same filing notes that, during Crowe’s engagement and the related periods described, there were no disagreements with Crowe on accounting principles, financial statement disclosure, or auditing scope or procedure that would have required reference in Crowe’s reports, and no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K. The company also requested, and filed as an exhibit, a letter from Crowe addressed to the SEC regarding the disclosures about the change in auditor.
How this relates to HROWM investors
For investors evaluating HROWM senior notes, the information about Harrow, Inc.’s auditor transition provides insight into the company’s financial reporting oversight. The absence of reported disagreements or reportable events with the prior auditor, as described in the filing, is part of the regulatory record surrounding the issuer of the HROWM notes. The listing of HROWM on The Nasdaq Stock Market LLC indicates that these notes are exchange-traded debt securities associated with Harrow, Inc. in the pharmaceutical preparations sector.
Frequently Asked Questions
Harrow, Inc. 11.875% Senior Notes due 2027 investment returns
How much was $1,000 invested in Harrow, Inc. 11.875% Senior Notes due 2027 worth at its last close?
If you invested $1,000 in Harrow, Inc. 11.875% Senior Notes due 2027 (HROWM) 1 year before its last close, on 2024-10-09, your investment was worth $968 on 2025-10-08, a -3.2% price return without dividends, growing at a compounded rate of -3.2% per year (CAGR).
Has Harrow, Inc. 11.875% Senior Notes due 2027 outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare HROWM performance over available time periods.
What is Harrow, Inc. 11.875% Senior Notes due 2027's average annual return?
The compound annual growth rate (CAGR) of HROWM’s share price over the 1 year to Oct 8, 2025 is -3.2%, without dividends. Individual years vary a great deal, and HROWM’s best recent full year was 2023 (+2.9%) while the worst was 2024 (+1.6%).
For informational and educational purposes only, not investment advice.
